Conference Proceedings

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, Matthew Greenwood, Glen A Kennedy, Sam Milliken, David Gottlieb, David Ritchie, Duncan Purtill, Stephen R Larsen, Andrew Spencer, Travis Perera, David T Yeung, Simon Durrant, Andrew Butler, Anne-Marie Watson, Hock Choong Lai, Richard Doocey, Hugh J Goodman, Ian H Kerridge, Christopher Arthur, Cameron Curley Show all

Blood | American Society of Hematology | Published : 2020


Introduction A majority of patients with diffuse large B cell lymphoma (DLBCL) will be cured with frontline chemoimmunotherapy, however a significant number of patients will relapse. Although autologous haematopoietic stem cell transplantation (autoHCT) may lead to sustained survival in some relapsing patients, long term survival with relapsed DLBCL is approximately 25% (Larouche et al., J Clin Oncol 2010;28(12):2094). Allogeneic HCT (alloHCT) is a potential treatment strategy in some DLBCL patients with relapsed disease. We performed a retrospective national registry study to examine alloHCT practice and outcomes for DLBCL in Australia and New Zealand in the mo..

View full abstract